Syncona is pleased to announce the completion of the sale of Gyroscope to Novartis. Key highlights include:

  • Up front cash payment of $800 million (£587 million) has been paid. In addition, up to $700 million (£514 million) in cash is potentially due upon the achievement of certain milestones
  • Transaction generates upfront cash proceeds of $442 million (£325 million) for Syncona's holding in Gyroscope
  • Syncona's risk adjusted and discounted valuation of the milestone payments from the transaction is $64 million (£47 million)

Syncona is also positioned to benefit from any future commercialisation of Gyroscope's lead programme via a low single digit royalty on future sales revenue.

For full details please see here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Syncona Ltd. published this content on 18 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 February 2022 07:10:02 UTC.